See more : Hyprop Investments Limited (HYP.JO) Income Statement Analysis – Financial Results
Complete financial analysis of Akero Therapeutics, Inc. (AKRO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Akero Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Specificity, Inc. (SPTY) Income Statement Analysis – Financial Results
- Investeringsforeningen C Worldwide Indien Kl (CWIIA.CO) Income Statement Analysis – Financial Results
- A1 Group, Inc. (AWON) Income Statement Analysis – Financial Results
- EnviroGold Global Limited (NVRO.CN) Income Statement Analysis – Financial Results
- Bioextrax AB (publ) (BIOEX.ST) Income Statement Analysis – Financial Results
Akero Therapeutics, Inc. (AKRO)
About Akero Therapeutics, Inc.
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 29.00K | 260.00K | 244.00K | 213.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -29.00K | -260.00K | -244.00K | -213.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 141.80M | 85.28M | 81.76M | 64.92M | 37.05M | 11.88M | 3.49M |
| General & Administrative | 31.07M | 29.87M | 19.13M | 15.24M | 8.61M | 1.90M | 1.18M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -98.00K |
| SG&A | 31.07M | 29.87M | 19.13M | 15.24M | 8.61M | 1.90M | 1.08M |
| Other Expenses | 0.00 | 3.86M | 109.00K | 947.00K | 1.90M | -67.94M | 0.00 |
| Operating Expenses | 172.87M | 115.16M | 100.89M | 80.15M | 45.65M | 13.78M | 4.56M |
| Cost & Expenses | 172.87M | 115.16M | 100.89M | 80.15M | 45.65M | 13.78M | 4.56M |
| Interest Income | 24.21M | 3.86M | 109.00K | 947.00K | 1.90M | 0.00 | 0.00 |
| Interest Expense | 3.10M | 739.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 29.00K | 260.00K | 244.00K | 213.00K | -104.00K | 13.78M | 4.98M |
| EBITDA | -148.63M | -111.03M | -100.53M | -78.99M | -45.65M | -68.46M | -232.36K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -172.87M | -115.16M | -100.89M | -80.15M | -45.65M | -13.78M | -4.56M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 21.11M | 3.12M | 109.00K | 947.00K | 1.90M | -67.94M | 0.00 |
| Income Before Tax | -151.76M | -112.03M | -100.78M | -79.21M | -43.76M | -81.71M | -4.56M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -3.12M | -41.00K | -17.00K | 24.00K | -68.10M | -4.98M |
| Net Income | -151.76M | -108.91M | -100.74M | -79.19M | -43.76M | -81.71M | -4.56M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.89 | -2.79 | -2.89 | -2.52 | -2.90 | -3.85 | -0.16 |
| EPS Diluted | -2.89 | -2.79 | -2.89 | -2.52 | -2.90 | -3.85 | -0.16 |
| Weighted Avg Shares Out | 52.57M | 38.98M | 34.83M | 31.46M | 15.07M | 21.22M | 28.56M |
| Weighted Avg Shares Out (Dil) | 52.57M | 38.98M | 34.83M | 31.46M | 15.07M | 21.22M | 28.56M |
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Akero Therapeutics, Inc. - AKRO
NEW YORK , June 7, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Akero Therapeutics, Inc. ("Akero" or the "Company") (NASDAQ: AKRO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980,...
AKRO SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Akero Therapeutics, Inc. Investors to Join the Class Action Lawsuit!
NEW YORK, NY / ACCESSWIRE / June 7, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO) and...
AKERO THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. - AKRO
NEW ORLEANS, LA / ACCESSWIRE / June 6, 2024 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 25, 2024 to file lead...
Akero Therapeutics, Inc. Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm
Investors can contact the law firm at no cost to learn more about recovering their losses
AKRO: Akero Therapeutics, Inc. Investors Reminder: A Securities Fraud Class Action Lawsuit Was Filed Against Akero Therapeutics, Inc. - Contact Kessler Topaz Meltzer & Check, LLP
RADNOR, PA / ACCESSWIRE / June 6, 2024 / The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Northern...
Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm
NEW YORK, June 06, 2024 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for potential violations of the federal securities laws.
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics
NEW YORK , June 6, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Akero Therapeutics, Inc. ("Akero" or the "Company") (NASDAQ: AKRO) and reminds investors of the June 25, 2024...
AKRO SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Akero Therapeutics, Inc. Investors to Join the Class Action Lawsuit!
NEW YORK, NY / ACCESSWIRE / June 6, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO) and...
AKERO THERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. – AKRO
NEW ORLEANS, June 05, 2024 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until June 25, 2024 to file lead plaintiff applications in a securities class action lawsuit against Akero Therapeutics, Inc. (NasdaqGS: AKRO),...
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKRO
NEW YORK , June 5, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Akero Therapeutics, Inc. (NASDAQ: AKRO) between September 13, 2022 and October 9, 2023, both dates inclusive (the...
Source: https://incomestatements.info
Category: Stock Reports